Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Kairos Pharma (KAPA) FCF Margin (2024 - 2025)

Historic FCF Margin for Kairos Pharma (KAPA) over the last 2 years, with Q1 2025 value amounting to 0.71%.

  • Kairos Pharma's FCF Margin rose 2242900.0% to 0.71% in Q1 2025 from the same period last year, while for Jun 2025 it was 5.37%, marking a year-over-year change of. This contributed to the annual value of 3.96% for FY2024, which is 1889000.0% up from last year.
  • Kairos Pharma's FCF Margin amounted to 0.71% in Q1 2025, which was up 2242900.0% from 376.16% recorded in Q3 2024.
  • Kairos Pharma's FCF Margin's 5-year high stood at 1400.0% during Q2 2024, with a 5-year trough of 225.0% in Q1 2024.